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Abstract
Background: Vascular dementia (VaD) is the second most common subtype of dementia after Alzheimer's disease
(AD). Currently, there are no medications approved for treating patients with VaD. Fufangdanshen (FFDS) tablets (Radix
Salviae miltiorrhizae formula tablets) are a traditional Chinese medicine that has been reported to improve memory.
However, the existing evidence for FFDS tablets in clinical practice derives from methodologically flawed studies. To
further investigate the safety, tolerability, and efficacy of FFDS tables in the treatment of mild to moderate VaD, we
designed and reported the methodology for a 24-week randomized, double-blind, parallel, multicenter study.
Methods/design: This ongoing study is a double-blind, randomized, parallel placebo-controlled trial. A total of 240
patients with mild to moderate VaD will be enrolled. After a 2-week run-in period, the eligible patients will be
randomized to receive either three FFDS or placebo tablets three times per day for 24 weeks, with a follow-up
12 weeks after the last treatment. The primary efficacy measurement will be the Alzheimer’s Disease Assessment
Scale-cognitive subscale (ADAS-cog) and the Clinician Interview-Based Impression of Change (CIBIC-plus). The
secondary efficacy measurements will include the Mini Mental State Examination (MMSE) and activities of daily
living (ADL). Adverse events will also be reported.
Discussion: This randomized trial will be the first rigorous study on the efficacy and safety of FFDS tablets for treating
cognitive symptoms in patients with VaD using a rational design.
Trial registration: ClinicalTrials.gov: NCT01761227. Registered on 2 January 2013.
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Background
Vascular dementia (VaD) is the second most com-
mon subtype of dementia after Alzheimer's disease
(AD) [1], and it accounts for 11.1–15.8 % of all cases
of dementia worldwide [2, 3]. The EURODEM Preva-
lence Research Group compared the prevalence of
VaD in five datasets from Europe (Finland, Italy,
Sweden, and two from the United Kingdom) and
found that the prevalence ranged from 0.0–1.6 % for
those aged between 60 and 70 years and increased
to 2.8–9.2 % for subjects aged 80–90 years. The an-
nual incidence rate was estimated to be 3.79 per
1000 among non-demented populations. At present,
the treatment of VaD focuses on primary and sec-
ondary prevention strategies because randomized
clinical trials in VaD have not been able to demon-
strate clinically relevant symptomatic improvement.
Additionally, it has not yet been possible to establish
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disease-modifying effects in VaD syndrome [4]. Thus,
the development of an effective treatment for VaD is
important.
Fufangdanshen tablets (FFDS), a traditional herbal
medicine approved by the China Food and Drug Ad-
ministration (CFDA) in 2008 (Number: [2008]1919),
are extracted from the Chinese herbs Salvia miltior-
rhiza, Panax notoginseng, and Borneolum syntheticum
and contain tanshinone, salvianolic acid, panax noto-
ginsenosides, ginsenoside Rb1, ginsenoside Rg1, and
borneol. The tablets are used to treat patients with
VaD. Preclinical studies have shown that tanshinone
can improve the impaired learning and memory in-
duced by Aβ1-40 in rat models of AD [5], inhibiting
AD-induced expression levels of inducible nitric oxide
synthase (iNOS) and matrix metalloproteinase II
(MMP-2), reducing toxic free radicals, and suppress-
ing oxidative injury in AD rats [6]. Salvianolic acid
can inhibit glutamate release and anti-cerebral ische-
mic effects [7]. Borneol can improve the permeability
of the blood-brain barrier [8].
Many studies have reported that FFDS tablets can
improve the memory of demented mice [9] and im-
prove the impairment of spatial discrimination and
memory impairment in rat models of AD. The
mechanisms may involve improvement in the brain
choline acetyl transferase (ChAT) activity that is de-
creased in AD rats and induced by Aβ [10], lowering
the toxicity of excitatory amino acids [11] and in-
creasing the expression of vascular endothelial
growth factor (VEGF) in the brains of rats during
chronic cerebral ischemia [11]. Additionally, FFDS
tablets could improve the learning and memory cap-
abilities in rat models of VaD, increase the activity
of superoxide dismutase, and reduce neuron apop-
tosis in the hippocampus [12].
A phase II clinical trial on the efficacy of FFDS
tablets in VaD was carried out in five centers. The
trial enrolled 231 patients; all patients were random-
ized to the FFDS tablets group (115 patients) or the
dihydroergotoxine mesylate tablets group (116 pa-
tients). Scores on the Mini Mental State Examination
(MMSE) [13] and activities of daily living signifi-
cantly improved in both groups compared with base-
line (P < 0.001). However, there were some
limitations to this study. First, there was no placebo
group. As all subjects knew that they were being
treated with one of two drugs and all of the individ-
uals who assessed the patients knew this as well, the
results may have been influenced by a positive re-
sponse bias. Second, the sample size was relatively
small. Third, this previous study only followed up
patients for 12 weeks, and this period of follow-up
was too short to detect the effects of the drugs.
To further investigate the safety, tolerability, and effi-
cacy of FFDS tablets in the treatment of mild to moder-
ate VaD, we designed and report the methodology for a




This ongoing study was designed as a randomized,
double-blind, parallel, placebo-controlled, multicenter
trial (six centers). It involves a single-blind run-in (and
washout) period using placebo only (2 weeks) and a
double-blind treatment phase after randomization
(24 weeks). The study is being carried out at six cen-
ters in China. It has been approved by the China
Food and Drug Administration (code: SFDA [2008]
I919) and also by the Institutional Review Board of
Dongzhimen Hospital, Beijing University of Chinese
Medicine and has been registered with Clinical-
Trials.gov (ClinicalTrials.gov: NCT01761227). If
there is any amendment to the protocol, approval
must again be sought from the Ethics Committee.
The patients and responsible caregivers will provide
written informed consent. The study will be con-
ducted according to Good Clinical Practice Guide-
lines and the principles of the Declaration of
Helsinki. The protocol design is based on the guide-
lines of Consolidated Standards of Reporting Trials
(CONSORT), and the study results will also be re-
ported according to these guidelines.
Participants
This trial will enroll both outpatient and inpatient
Chinese-speaking males and females aged 45–80
years old, weighing 45–90 kilograms, and meeting
the diagnostic criteria of probable VaD established
according to the Diagnostic and Statistical Manual of
Mental Disorders, 4th edition (DSM-IV) [14], the
National Institute of Neurological Disorders and
Stroke, and the Association Internationale pour la
Recherche et l’Enseignement en Neurosciences
(NINDS-AIREN) [15].
Participants’ inclusion criteria are described as follows:
1. Dementia
(a) Global cognitive impairment and defects in at
least one other cognitive domain such as
executive function/attention, information
processing speed, visual spatial ability,
language and memory, which can be
confirmed by clinical and neuropsychological
assessment, and
(b) Cognitive impairment severe enough to interfere
daily living and functioning
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2. Cerebral vascular diseases, such as clear
neuroimaging (MRI or CT) evidence of ischemic
stroke, including infarct in the main blood
vessels, single strategic infarct (e.g., thalamus,
angular gyrus, and basal forebrain), multiple
lacunar infarcts, and/or extensive white matter
damage surrounding ventricles (≥25 % of all
white matter area). Focal neurological signs that
can be explained by stroke are also necessary,
such as hemiplegia, anesthesia, hemianopia,
dysarthria, facial paralysis, and positive reflex of
Babinski’s sign
3. Correlation between dementia and cerebral vascular
diseases
(a)The dementia occurs within 3 months following a
stroke, or
(b)Evidence of sudden onset, stepwise progression,
focal cortical deficits on neuropsychological
assessment, and
(c)Hachinski Ischemic Scale (HIS) score
>4 [16] and 6-month VaD duration
before inclusion
4. Severity of dementia assessed as mild to
moderate as defined by a score of 11 to 26 on
the MMSE [13]
5. Patients must have adequate vision and hearing to
participate in study assessments
Patients who confirm any of the following exclud-
ing criteria conditions will not be enrolled in the
study: subjects with AD and any other secondary
types of dementia (e.g., post-traumatic dementia, de-
mentia associated with Parkinson’s disease, or cere-
bral tumor); depressive pseudodementia and other
mental disorders; a history of epilepsy; patients suf-
fering from psychotic episodes; psychomotor excita-
tion; MRI scans not showing vascular lesions in the
brain; a history of drug or alcohol abuse in the past
6 months; acute or uncontrolled chronic illnesses;
history of hypersensitivity to the treatment drugs;
concomitant drugs with the potential to interfere
with the study outcomes (including anticonvulsant
agents, psychotropic drugs, drugs with psychiatric
side effects, anticoagulants, cholinomimetic agents,
short-acting benzodiazepines, or any other drugs that
contain Salvia miltiorrhiza, Panax notoginseng, and/
or Borneolum syntheticum); participation in another
clinical study.
All subjects will undergo an MRI scan before
they are randomized. Participants will be excluded
if the MRI presents medial temporal lobe atrophy
adjusted for age. Scans will be performed routinely
at each site and will be considered adequate if the
images are of sufficient technical quality to be read
accurately for the purposes of determining study
inclusion. After receiving this imaging information,
investigators will consider the clinical history,
examination, and laboratory evaluations to assign
the designation of “probable VaD” or “possible
VaD.”
Study medication
All trial medication will be supplied by the Hutchison
Whampoa Guangzhou Baiyunshan Chinese Medicine
Company Limited (China). The FFDS tablets are com-
posed of Salvia miltiorrhiza (DanShen in Chinese),
Panax pseudo-ginseng (SanQi in Chinese), and Borneo-
lum syntheticum (BingPian in Chinese). Each tablet
weighs 0.3 g and contains tanshinone, salvianolic
acid, panax notoginsenosides, ginsenoside Rb1, ginse-
noside Rg1, and borneol. The FFDS tables were pro-
duced in a single batch (batch number: 080401,
Placebo batch number: 081101) in strict compliance
with standards of Good Manufacturing Practice
(GMP).
During the 2-week placebo washout period, all
patients will receive three placebo tablets three
times per day. During the double-blind, 24-week
intervention, the patients will receive either three
FFDS or placebo tablets (three times per day), at
least 2 hours apart from taking any routine West-
ern medication. To preserve blinding, the placebo
tablets have an identical taste and appearance to
the FFDS tablets.
Concomitant use of anticonvulsants, antipsychotics,
cholinomimetic drugs, anticholinergic agents, anti-
Parkinson drugs, cholinesterase inhibitors, memantine,
nootropic drugs, nimodipine, other cognition enhancers,
or any drugs containing Salvia miltiorrhiza and Panax
notoginseng will be forbidden. The investigator must
record the concomitant drugs, including the name of the
drug, daily dose, reason for using, and date of
termination.
Sample size calculations
Because there are few studies on the treatment of
VaD, the sample size was calculated based on data
from a study of AD treatment using the Alzheimer’s
Disease Assessment Scale-cognitive subscale (ADAS-
cog) [17]. The previous study reported that patients
who received donepezil (5 mg/day) showed a mean
improvement of 0.67 ± 0.51; the patients who re-
ceived the placebo showed a worse score of 1.82
points. Using a one-sided test with a significance
level of 0.05 and power of 90 %, the minimum num-
ber was 88 per group to detect a difference of 1.5
points on the ADAS-cog. To achieve an adequate
number to detect the safety of the FFDS tablets, the
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number of the patients was increased to 100 per
group. Considering a greater rate of discontinuation
of 20 %, the sample size was increased to 120 per
group to ensure adequate patients to complete the
study.
The randomization is stratified according to center
using SAS statistical software (version 9.13) (SAS In-
stitute Inc., Cary, NC, USA). Balanced randomization
generated by SAS statistical software is carried out
in three steps (in blocks of four) by a statistician
with no access to information on the patients or
physicians. Patients will be randomized in a ratio of
1:1 to receive the FFDS or placebo tablets. The ran-
domized code is generated in the randomization
process and sealed in an envelope. Statisticians as-
sign the medication group according to the
randomization code. Afterwards, the sealed
randomization codes and each available medication
number are sent out to each center. Blinding will be
broken only if a patient’s trial medication requires
specific emergency treatment. Once the blinding is
broken, the patient will be managed as off-trial.
Procedures
Two methods are being used to recruit participants with
VaD. The first source of subjects is from memory clinics
of six public hospitals of different centers, and the sec-
ond source is those who respond to advertisements pub-
lished in local newspapers. Figure 1 shows the schedule
of enrollment.
The neuropsychological assessments, laboratory de-
terminations, measurements of vital signs (including
temperature, blood pressure, and electrocardiogram),
and neurological tests (including an examination of
cranial nerves, motor coordination, muscle tonus,
and power) will be evaluated before patients are en-
rolled. The diagnosis of probable VaD will be based
on the neurological test and confirmed by the cri-
teria of the NIND-AIREN and DSM-IV, the HIS, and
the Hamilton Depression Rating Scale (HAMD) [18].
Fig. 1 Schedule of enrollment. ITT intent to treat
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For differential diagnosis, the Activities of Daily Liv-
ing (ADL) [19] and a scan of the brain are also
necessary.
All patients will receive an assessment at baseline
(0 week), 12 weeks, and 24 weeks, and an add-
itional assessment will be performed 12 weeks after
completing the assigned double-blind medication.
The study timeline and endpoints are shown in
Table 1.
Any adverse events will be recorded during the dur-
ation of the trial. Patients will receive four clinical
assessments.
Patients, caregivers, the study investigator, any other
personnel involved in the study, and the investigating
staff of the Hutchison Whampoa Guangzhou Baiyun-
shan Chinese Medicine Company Limited will remain
blinded until all patients complete the study and all data
are collected.
Efficacy measurements
The primary efficacy measurements are the ADAS-cog
[20] and the Clinician Interview-Based Impression of
Change (CIBIC-plus) [21]. The ADAS-cog contains 12
items dealing with word recall, naming objects and fin-
gers, commands, constructions and ideational praxis,
orientation, word recognition, spoken language ability
and comprehension of spoken language, word-finding
difficulty, and attention. The scores of the ADAS-cog
range from 0 to 75, and a higher score indicates higher
impairment.
The CIBIC-plus is used to assess the global clinical
status of the demented patient relative to baseline based
on information from a semi-structured interview with
the patient and the caregiver, and was designed specific-
ally to evaluate the severity of cognitive dysfunctions
characteristic of AD patients [21]. The score of the
CIBIC-plus ranges from 1 to 7; a score of 1–3 indicates
improvement, 4 means no change, and 5–7 indicates
decline.
The secondary efficacy measurements include the
MMSE and ADL [19]. The MMSE is used to as-
sess the extent of cognitive dysfunction. The ADL
mainly will be used to measure the basic activities
and the instrumental activities of daily living. The
ADL scale can be divided into the Physical Self-
Maintenance Scale (PSMS) and the Instrumental
Activities of Daily Living (IADL). The PSMS relates
to physical activities, such as toileting, mobility,
dressing, and bathing; the IADL contains eight
items, such as shopping, cooking, doing laundry,
handling finances, using the telephone, mode of
transportation, responsibility for own medication,
and housekeeping.
Safety assessment
Studies have reported that the adverse events of
FFDS tablets were as follows [22]: a total of 11 pa-
tients suffered adverse events. Five patients suffered
allergic reactions, such as rash or allergic asthma;
two patients suffered hypokalemia, with symptoms
Table 1 Study timeline and endpoints






Vital signs √ √ √ √ √
MMSE √ √ √ √ √
HAMD √
HIS √
ADAS-cog √ √ √ √
CIBIS √
CIBIC-plus √ √ √
ADL √ √ √ √
Safety measure √ √ √
Adverse event √ √ √
Concomitant drugs √ √ √ √
CIBIS Clinician Interview-Based Impression of Severity, CIBIC-plus Clinician Interview-Based Impression of Change
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like bloating and fatigue; one patient also showed
significant sinus bradycardia, one patient showed
tuberculosis hemoptysis, one showed thrombocytopenia,
and one patient suffered hematuria with back pain and
fever.
Safety will be assessed at baseline (week 0), mid-
study (week 12), and at the end of treatment
(week 24). The safety assessment will include the
following: (1) physical examination of vital signs,
including breathing, heart rate, and blood pressure;
(2) electrocardiography; (3) laboratory testing, in-
cluding urine and blood; and (4) any adverse
events that may occur, including the types of ad-
verse events, time of occurrence, duration, treat-
ment measures, and evaluation of the correlation
between the tested drugs and the adverse event
(positive, probable, possible, or not correlated); the
severity of the adverse event (mild, moderate, and
severe) must be evaluated. A mild adverse event is
described as one that could induce mild symptoms,
but the symptoms could be well tolerated, and
there is no necessity to receive treatment or dis-
continue the study drugs. A moderate adverse
event is defined as symptoms that could not be
well tolerated and could affect the subject’s ADLs;
a moderate adverse event means that the tested
drug must be stopped. Severe adverse events in-
clude any event that is fatal, considered to be life-
threatening, or requires hospitalization.
Compliance strategy
To maximize subjects’ compliance, we will try to
prevent dropouts by providing ongoing support to
patients. A direct telephone line set up for this
clinical trial will enable the study team to commu-
nicate personally with the patients. If a patient is
lost to follow-up, we will call to ask the reason
and attempt to schedule a meeting at the patient’s
convenience.
Statistical analysis
Statistical analyses will be conducted in three pop-
ulations. The intent-to-treat (ITT) population will
consist of all of the randomized population who
take at least one dose of medication and at least
one primary efficacy evaluation on treatment. The
fully evaluated (FE) population will include all ran-
domized patients who have received at least 80 %
of the assigned 24 weeks of double-blind medica-
tion with a complete record of efficacy variables,
with no major protocol violations. The safety set
(SS) population will include all of the randomized
population who receive at least one dose of the
study medication, with at least one safety record post
baseline.
The efficacy analysis will be conducted with the
ITT and FE populations. The ADAS-cog and
CIBIC-plus will be analyzed using the last observa-
tion carried forward (LOCF) method for the re-
placement of missing observations. The ADAS-cog
and MMSE will be assessed by analysis of covari-
ance (ANCOVA) with baseline scores as covariates
and the treatment group and center as factors. The
Cochran–Mantel–Haenszel test will be used for
CIBIC-plus scores. The occurrence of adverse
events will be analyzed using frequency calculations
and descriptive statistics.
Discussion
Currently, there is no medication approved for treat-
ing patients with VaD. This ongoing randomized,
placebo-controlled, 24-week clinical trial will be the
first rigorous testing of FFDS tablets for the treat-
ment of patients with VaD. Success in this clinical
trial will provide evidence for the use of FFDS tab-
lets in the treatment of VaD.
A series of neuropathological studies have shown
that the diagnostic accuracy of the NINDS-AIREN
criteria is 90 %, and the sensitivity is 0.20–0.58 [23,
24]; the HIS also showed high specificity (87–95 %)
and a relatively lower sensitivity for the diagnosis of
VaD (43–50 %) [24, 25]. Thus, in the present on-
going study, the diagnosis of VaD is based on the
criteria of the NINDS-AIREN and the HIS. Addition-
ally, the present study uses structural neuroimaging
to differentiate VaD from AD to enroll proper VaD
subjects.
The United States Food and Drug Administration
(FDA) and the European Medicines Agency (EMA)
have issued guidelines on the criteria of efficacy with
symptomatic improvement clinical trials [26–28].
Both of these guidelines emphasize three domains as
efficacy endpoints: cognition endpoint, ADLs (func-
tional endpoint), and overall clinical response as
reflected by global assessment (global endpoint).
Based on these guidelines, in the present study we
are using each of these three endpoints as efficacy
endpoints. In conclusion, the results of the present
study are expected to provide evidence for the effi-
cacy and safety of FFDS tablets for the treatment of
patients with VaD.
Trial status
The trial has been approved and registered. At the time
of manuscript submission, the study has been actively
enrolling subjects and, as of this writing, has a total of
212 subjects. The study is ongoing.
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Appendix
Table 2 Proposed elaborations of CONSORT items for randomized, controlled trials of FFDS tablets interventions
Paper section and
topic
Item number Descriptor Reported on
page number
Title and Abstract 1 How participants were allocated to interventions (e.g., “random allocation,”
“randomized,” or “randomly assigned”)
1,3
Either the title or abstract, or both, should state the herbal medicinal product’s
Latin binomial, the part of the plant used, and the type of preparation
Introduction
Background 2 Scientific background and explanation of rationale 4,5
Including a brief statement of reasons for the trial with reference to the specific
herbal medicinal product being tested and, if applicable, whether new or
traditional indications are being investigated
Methods
Participants 3 Eligibility criteria for participants and the settings and locations where the data
were collected
5,6
If a traditional indication is being tested, a description of how the traditional
theories and concepts were maintained. For example, participant inclusion criteria
should reflect the theories and concepts underlying the traditional indication
Interventions 4 Precise details of the interventions intended for each group and how and when
they were actually administered
4A: Herbal medicinal
product name
1. The Latin binomial name and the botanical authority and family name for each
herbal ingredient; common name(s) should also be included
6
2. The proprietary product name (i.e., brand name) or the extract name (e.g., EGb-
761) and the name of the manufacturer of the product
3. Whether the product used is authorized (licensed, registered) in the country in
which the study was conducted
4B: Characteristics of the
herbal product
1. The part(s) of plant used to produce the product or extract
2. The type of product used (e.g., raw [fresh or dry], extract)
3. The type and concentration of extraction solvent used (e.g., 80 % ethanol,
100 % H2O, 90 % glycerin, etc.) and the ratio of herbal drug to extract (e.g., 2 to 1)
4. The method of authentication of raw material (i.e., how done and by whom)
and the lot number of the raw material. State if a voucher specimen (i.e., retention
sample) was retained and, if so, where it is kept or deposited, and the reference
number
4C: Dosage regimen and
quantitative description
1. The dosage of the product, the duration of administration, and how these were
determined
6,7
2. The content (e.g., as weight, concentration; may be given as range where
appropriate) of all quantified herbal product constituents, both native and added,
per dosage unit form. Added materials, such as binders, fillers, and other
excipients (e.g., 17 % maltodextrin, 3 % silicon dioxide per capsule), should also be
listed)
3. For standardized products, the quantity of active/marker constituents per
dosage unit form
4D: Qualitative testing 1. Product’s chemical fingerprint and methods used (equipment and chemical
reference standards) and who performed the chemical analysis (e.g., the name of
the laboratory used). Whether a sample of the product (i.e., retention sample) was
retained and if so, where it is kept or deposited
No
2. Description of any special testing/purity testing (e.g., heavy metal or other
contaminant testing) undertaken; which unwanted components were removed
and how (methods)
3. Standardization: what to standardize (e.g., which chemical components of the
product) and how (e.g., chemical processes, or biological/functional measures of
activity)
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